Cargando…
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determin...
Autores principales: | Driouich, Jean-Sélim, Cochin, Maxime, Lingas, Guillaume, Moureau, Grégory, Touret, Franck, Petit, Paul-Rémi, Piorkowski, Géraldine, Barthélémy, Karine, Laprie, Caroline, Coutard, Bruno, Guedj, Jérémie, de Lamballerie, Xavier, Solas, Caroline, Nougairède, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979801/ https://www.ncbi.nlm.nih.gov/pubmed/33741945 http://dx.doi.org/10.1038/s41467-021-21992-w |
Ejemplares similares
-
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
por: Cochin, Maxime, et al.
Publicado: (2022) -
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
por: Touret, Franck, et al.
Publicado: (2021) -
The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
por: Cochin, Maxime, et al.
Publicado: (2022) -
A simple reverse genetics method to generate recombinant coronaviruses
por: Mélade, Julien, et al.
Publicado: (2022) -
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
por: Driouich, Jean-Sélim, et al.
Publicado: (2022)